

# Michael Recht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3738641/publications.pdf>

Version: 2024-02-01

40  
papers

3,364  
citations

567281

15  
h-index

302126

39  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3010  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. <i>New England Journal of Medicine</i> , 2007, 357, 535-544.	27.0	1,681
2	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. <i>New England Journal of Medicine</i> , 2014, 371, 1994-2004.	27.0	1,063
3	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , 2019, 3, 3241-3247.	5.2	85
4	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. <i>Blood Advances</i> , 2020, 4, 2451-2459.	5.2	67
5	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. <i>Value in Health</i> , 2012, 15, 916-925.	0.3	47
6	Differences in Platelet $\alpha$ -granule Release between Normals and Immune Thrombocytopenic Patients and between Young and Old Platelets. <i>Thrombosis and Haemostasis</i> , 1998, 80, 457-462.	3.4	38
7	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. <i>European Journal of Haematology</i> , 2018, 100, 5-13.	2.2	37
8	Current Options and New Developments in the Treatment of Haemophilia. <i>Drugs</i> , 2011, 71, 305-320.	10.9	34
9	Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). <i>Haemophilia</i> , 2019, 25, 382-391.	2.1	28
10	Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (BHERO) study. <i>European Journal of Haematology</i> , 2017, 98, 5-17.	2.2	25
11	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 897-911.	1.7	21
12	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). <i>Value in Health</i> , 2014, 17, 744-748.	0.3	20
13	Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1369-1380.	1.8	20
14	The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. <i>American Journal of Hematology</i> , 2020, 95, 960-965.	4.1	19
15	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1603-1612.	1.8	15
16	Community counts: Evolution of a national surveillance system for bleeding disorders. <i>American Journal of Hematology</i> , 2018, 93, E137-E140.	4.1	15
17	Delirium in the pediatric hematology, oncology, and bone marrow transplant population. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27640.	1.5	15
18	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. <i>Blood Advances</i> , 2021, 5, 2732-2739.	5.2	11

#	ARTICLE	IF	CITATIONS
19	Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. <i>Value in Health</i> , 2021, 24, 1628-1633.	0.3	11
20	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. <i>American Journal of Hematology</i> , 2017, 92, 646-652.	4.1	10
21	Patient-reported outcomes and joint status across subgroups of <sc>US</sc> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P&FiQ) study. <i>European Journal of Haematology</i> , 2018, 100, 14-24.	2.2	10
22	Building the blueprint: Formulating a community-generated national plan for future research in inherited bleeding disorders. <i>Haemophilia</i> , 2022, 28, 760-768.	2.1	10
23	Results of genetic analysis of 11%341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2022-2034.	3.8	10
24	Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. <i>Journal of Blood Medicine</i> , 2014, 5, 55.	1.7	9
25	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. <i>Journal of Medical Economics</i> , 2021, 24, 363-372.	2.1	8
26	Thrombocytopenia and Anemia in Infants and Children. <i>Emergency Medicine Clinics of North America</i> , 2009, 27, 505-523.	1.2	7
27	Epistaxis as a Common Presenting Symptom of Glanzmann's Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. <i>Case Reports in Emergency Medicine</i> , 2017, 2017, 1-6.	0.3	6
28	The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. <i>Haemophilia</i> , 2019, 25, 590-594.	2.1	6
29	Incorporating the patient voice and patient engagement in GOAL's: Advancing patient-centric hemophilia care. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12655.	2.3	5
30	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. <i>Blood Advances</i> , 2020, 4, 4739-4747.	5.2	4
31	Management of inhibitors in persons with nonsevere hemophilia <sc>A</sc> in the <sc>United States</sc>. <i>American Journal of Hematology</i> , 2021, 96, E9-E11.	4.1	4
32	Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOsc). <i>Blood</i> , 2013, 122, 210-210.	1.4	4
33	Resource utilization and treatment costs of patients with severe hemophilia A: Real-world data from the ATHNdataset. <i>EJHaem</i> , 2022, 3, 341-352.	1.0	4
34	The GOAL's journey: Shared decision making and patient-centred outcomes. <i>Haemophilia</i> , 2022, 28, 784-795.	2.1	4
35	Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. <i>Pediatric Research</i> , 2018, 83, 693-701.	2.3	3
36	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1035-1045.	2.3	3

#	ARTICLE	IF	CITATIONS
37	A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal of Blood Medicine, 2021, Volume 12, 883-896.	1.7	3
38	A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors. Journal of Blood Medicine, 2021, Volume 12, 913-928.	1.7	1
39	Safety first: Tracking adverse events associated with new therapies for people with hemophilia. Journal of Thrombosis and Haemostasis, 2021, 19, 3-5.	3.8	1
40	Why plasma-derived factor VIII?. Haemophilia, 2019, 25, e183-e185.	2.1	0